Tyra Biosciences (NASDAQ:TYRA – Get Free Report) had its price objective increased by analysts at HC Wainwright from $25.00 to $30.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 38.63% from the stock’s previous close.
Several other equities research analysts have also recently issued reports on the stock. Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Thursday, August 8th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.80.
Read Our Latest Research Report on Tyra Biosciences
Tyra Biosciences Stock Performance
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, research analysts predict that Tyra Biosciences will post -1.53 earnings per share for the current year.
Insider Activity
In other news, CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 16,890 shares of company stock valued at $408,444 in the last 90 days. 15.40% of the stock is currently owned by insiders.
Institutional Trading of Tyra Biosciences
A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its holdings in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the period. Wellington Management Group LLP increased its position in shares of Tyra Biosciences by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after acquiring an additional 8,324 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Tyra Biosciences in the 3rd quarter valued at $311,000. Bank of New York Mellon Corp lifted its holdings in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares in the last quarter. Finally, HighVista Strategies LLC purchased a new stake in Tyra Biosciences during the 2nd quarter worth $257,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Further Reading
- Five stocks we like better than Tyra Biosciences
- How to buy stock: A step-by-step guide for beginners
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- High Dividend REITs: Are They an Ideal Way to Diversify?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- How to Use the MarketBeat Stock Screener
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.